39 studies found for:    "Paroxysmal nocturnal hemoglobinuria"
Show Display Options
Rank Status Study
1 Recruiting Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Condition: Paroxysmal Nocturnal Hemoglobinuria
Intervention:
2 Completed Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   PNH
Intervention:
3 Unknown  Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
Conditions: Rheologic Disease;   Sickle Cell Disease;   Paroxysmal Nocturnal Hemoglobinuria
Intervention: Other: Imaging
4 Active, not recruiting Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   Hemoglobinuria;   Hemoglobinuria, Paroxysmal;   Proteinuria;   Urination Disorders;   Thrombosis;   Bone Marrow Failure;   Aplastic Anemia,;   Anemia, Hemolytic
Interventions: Drug: Levamisole+cyclosporin A+Glucocorticoids;   Drug: cyclosporin A+Glucocorticoids;   Drug: Glucocorticoids
5 Completed C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Condition: Paroxysmal Nocturnal Hemoglobinuria
Intervention: Drug: Eculizumab
6 Completed E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Condition: Paroxysmal Nocturnal Hemoglobinuria
Intervention: Drug: Eculizumab
7 Active, not recruiting Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   Hemoglobinuria;   Hemoglobinuria, Paroxysmal;   Proteinuria;   Urination Disorders;   Thrombosis;   Bone Marrow Failure;   Aplastic Anemia,;   Anemia, Hemolytic
Interventions: Drug: Levamisole+cyclosporin A+Glucocorticoids;   Drug: cyclosporin A+Glucocorticoids;   Drug: Glucocorticoids
8 Completed Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria
Intervention:
9 Terminated Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Drug: ALXN1102;   Drug: ALXN1103
10 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Intervention: Drug: Eculizumab
11 Unknown  Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Conditions: Aplastic Anemia;   Paroxysmal Hemoglobinuria, Nocturnal
Interventions: Drug: cyclophosphamide;   Drug: filgrastim
12 Unknown  Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria
Condition: Paroxysmal Nocturnal Haemoglobinuria
Intervention:
13 Completed Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Intervention: Drug: eculizumab
14 Recruiting Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Intervention: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
15 Completed Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
Conditions: Allogeneic Stem Cell Transplant;   Leukemia;   Non-Hodgkins;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Drug: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
16 Completed The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Hemoglobinuria, Paroxysmal
Intervention:
17 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: Eculizumab
18 Recruiting Unrelated Donor Stem Cell Transplantation
Conditions: Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
Intervention: Procedure: Allogeneic transplantation
19 Completed Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
Conditions: Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Paroxysmal Nocturnal Hemoglobinuria;   Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Drug: Systematic chemotherapy and antibodies;   Procedure: Allogeneic stem cell transplantation;   Device: Miltenyi CliniMACS
20 Completed Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Paroxysmal Nocturnal Hemoglobinuria;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Relapsing Chronic Myelogenous Leukemia;   Thrombocytopenia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: bryostatin 1;   Biological: sargramostim;   Other: laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years